LYCOS RETRIEVER 
Wyeth: Wyeth Pharmaceuticals
built 815 days ago
Despite these problems, AHP, which changed its name to Wyeth in 2002, entered the 21st century with a strong pharmaceutical franchise. With strengths in vaccines, biotechnology, and traditional pharmaceuticals, Wyeth's products spanned a wide range of treatment areas, and, on average, its pharmaceuticals had one of the longest remaining patent lives in the industry. It had about 60 potential products in its research pipeline. It had a powerful presence in the consumer health market. Through its Fort Dodge division, Wyeth ... maintained a significant presence in the animal health market.
Source:
Wyeth-Ayerst Pharmaceuticals is renovating its 1.2 million square-foot Collegeville, Pennsylvania, headquarters and R&D campus. Wyeth intends to make the campus a benchmark for resource efficiency and sustainability. To help meet this goal, Wyeth is investigating conducting a comparative study of low-flow fume hoods in various "as installed" bays at its Collegeville, Pennsylvania, facility. This project could include ASHRAE 110 testing, as well as computational fluid dynamics modeling.
Source:
COLLEGEVILLE, Pa., March 23 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), salutes the World Health Organization's (WHO) decision to support the inclusion of pneumococcal conjugate vaccine (PCV) in national immunization programs worldwide. In view of the demonstrated vaccine efficacy and high disease burden, WHO notes that PCV can help substantially reduce mortality and morbidity. Pneumococcal disease is a significant concern to children's health, estimated by WHO to result in up to 1 million deaths each year in young children around the world.
Source:
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), will examine the safety of its novel investigational recombinant antibody MYO-029 in a phase one/two clinical trial in adult patients with muscular dystrophy (MD). The trial is open to adult patients with facioscapulohumeral MD (FSHD), Becker MD (BMD) and limb-girdle MD (LGMD); further details are available at http://www.clinicaltrials.gov. Results of the study are expected to be available in late 2006.
Source:
"Wyeth remains committed to the development of Pristiq as a potential treatment for moderate-to-severe vasomotor symptoms associated with menopause," says Gary L. Stiles, M.D., Executive Vice President and Chief Medical Officer, Wyeth Pharmaceuticals. "We will work with the Agency to satisfy its requests for additional data and move the medicine forward in the FDA review process."
Source:
The FDA has accepted for review an NDA from Progenics Pharmaceuticals and Wyeth for subcutaneous methylnaltrexone for the treatment of opioid-induced constipation (OIC) in patients receiving palliative care. The FDA has set a Prescription Drug User Fee Act (PDUFA) date of January 30, 2008, to complete its review of the NDA. The companies ... announced that the European Medicines Agency (EMEA) has validated for review Wyeth’s Marketing Authorization Application (MAA) for the treatment.Methylnaltrexone, an investigational drug, is a peripherally acting opioid-receptor antagonist that is designed to treat OIC without interfering with pain relief. There currently is no approved medication that specifically targets the underlying cause of OIC to relieve constipation in this patient population. The acceptance of the NDA submission results in a $5 million milestone payment to Progenics by Wyeth. Progenics previously earned a $4 million milestone payment from Wyeth based on the validation for review in the EU, as announced previously.In December 2005, Wyeth and Progenics entered into an exclusive, worldwide agreement for the joint development and commercialization of methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative ileus (POI), a prolonged dysfunction of the gastrointestinal (GI) tract following surgery.
Source:
MORE ABOUT
Wyeth Pharmaceuticals